Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)
暂无分享,去创建一个
U. Syrbe | J. Braun | J. Listing | J. Sieper | K. Hermann | J. Callhoff | D. Poddubnyy | M. Rudwaleit | I. Song
[1] J. Braun,et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis , 2013, Annals of the rheumatic diseases.
[2] J. Reveille,et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. , 2013, Arthritis and rheumatism.
[3] E. Märker-Hermann,et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. , 2012, Arthritis and rheumatism.
[4] M. Dougados,et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis , 2012, Annals of the rheumatic diseases.
[5] E. Märker-Hermann,et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort , 2012, Annals of the rheumatic diseases.
[6] J. Bijlsma,et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis , 2011, Arthritis research & therapy.
[7] M. Dougados,et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.
[8] M. Dougados,et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis , 2010, Annals of the rheumatic diseases.
[9] R. Landewé,et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis , 2010, Annals of the rheumatic diseases.
[10] Gwo‐Jaw Wang,et al. Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. , 2009, Toxicology.
[11] M. Dougados,et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection , 2009, Annals of the rheumatic diseases.
[12] M. Dougados,et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine , 2008, Annals of the rheumatic diseases.
[13] M. Østergaard,et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. , 2009, Arthritis and rheumatism.
[14] J. Sieper,et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. , 2008, Arthritis and rheumatism.
[15] A. Schönthal,et al. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy , 2007, British Journal of Cancer.
[16] J. Braun,et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes , 2007, Annals of the rheumatic diseases.
[17] T. Perneger,et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. , 2007, The Journal of bone and joint surgery. British volume.
[18] L. Karol. Scoliosis in patients with Duchenne muscular dystrophy. , 2007, The Journal of bone and joint surgery. American volume.
[19] L. Claes,et al. The non-steroidal anti-inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats , 2007, Archives of Orthopaedic and Trauma Surgery.
[20] J. Bijlsma,et al. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study , 2005, Arthritis Research & Therapy.
[21] D. M. van der Heijde,et al. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. , 2005, The Journal of rheumatology.
[22] M. Dougados,et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. , 2005, Arthritis and rheumatism.
[23] C. Romanò,et al. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. , 2004, The Journal of arthroplasty.
[24] A. M. Simon,et al. Cyclo‐Oxygenase 2 Function Is Essential for Bone Fracture Healing , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] Gerd Geisslinger,et al. Cyclooxygenase‐independent actions of cyclooxygenase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] S. Vane. Differential inhibition of cyclooxygenase isoforms: an explanation of the action of NSAIDs. , 1998, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[27] A. Cats,et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.
[28] Boersma Jw. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. , 1976 .
[29] J. Boersma. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. , 1976, Scandinavian journal of rheumatology.
[30] E. L. Persons,et al. Ankylosing Spondylitis , 1955, GP.